Capital Advisors Ltd’s Seres Therapeutics MCRB Stock Holding History

Capital Advisors Ltd’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	1190
2022 Q1	$0	Buy	+1	New	+$154	﹤0.01%	1091

Other funds holding MCRB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Capital Advisors Ltd's MCRB Position: Q2 2022 in Review

Capital Advisors Ltd sold out of Seres Therapeutics (MCRB) in Q2 2022, closing a stake of 1 share.

Capital Advisors Ltd first reported a position in MCRB in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q2 2022.

Capital Advisors Ltd reported no remaining Seres Therapeutics position as of Q2 2022 after selling out during the quarter.
Capital Advisors Ltd sold 1 Seres Therapeutics share in Q2 2022.
Capital Advisors Ltd first reported a position in Seres Therapeutics in Q1 2022 and held it in 1 quarter.
Capital Advisors Ltd's Seres Therapeutics position peaked at $0 in Q1 2022.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2022.

Based on Capital Advisors Ltd's 13F filing for Q2 2022, filed 5 Aug 2022.